CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2023—Quest Diagnostics and Haystack Oncology, an early-stage oncology company focused on minimal residual disease testing, announced on April 27 a definitive agreement for Quest to acquire Haystack in an all-cash equity transaction.
Founded in 2021, Haystack has developed a ctDNA-based technology for MRD detection, based on 20 years of research and development work at Johns Hopkins University by Bert Vogelstein, MD, Ken Kinzler, PhD, and Nick Papadopoulos, PhD. In a prospective, multi-institution study published last year (Tie J, et al. N Engl J Med. 2022;386[24]:2261–2272), an earlier version of the Haystack technology was reported to be able to reduce the use of adjuvant chemotherapy without compromising recurrence-free survival.
Pages: 1 2